On November 12, 2022, the World Young Scientist Summit 2022 was held in Wenzhou, Zhejiang. At the opening ceremony, China Association for Science and Technology announced winners of the China Youth Science and Technology Award. Xu Feng, Vice President of Qilu Hospital of Shandong University (the First Clinical College) won the award.
The China Youth Science and Technology Award is jointly established and implemented by the Organization Department of the CPC Central Committee, Ministry of Human Resources and Social Security, China Association for Science and Technology, and Central Committee of the Communist Youth League. The award is meant to bring up a group of young academic and technological leaders who are at the forefront in the realm of science and technology globally, recognizing the contribution they have made to the development of economy, society, and science and technology in China. The prize is awarded every two years, and less than 100 winners is awarded each time.
Xu Feng, Vice President of Qilu Hospital of Shandong University, Vice Dean of the First Clinical College, Chief physician, Professor, Ph.D. supervisor, national talent title winner, chief expert of national major scientific research project, Excellent Physician of Shandong Province, member of the Standing Committee of Emergency Medicine Branch of Chinese Medical Association, member of the Standing Committee of Chest Pain Branch of Chinese Medical Doctor Association, Vice Chairman of Chest Pain Branch of China International Enhance and Promotive Association for Medical and Healthcare Association, Chairman of Emergency Medicine Branch of Shandong Provincial Medical Association, and Fellow (FACC, FESC) of American Heart Association and European Society of Cardiology, etc.
Prof. Xu Feng’s expertise and research interests are critical cardiovascular diseases and cardiac arrest. Over the past decade, he has been focusing on clinical and scientific research work of individualized prevention and treatment of critical cardiovascular diseases, achieved multiple original results, and actively applied the latest international research results and concepts of diagnosis and treatment to clinical work. He has been awarded the Outstanding Young Talent of Qilu Hospital, Young Post Expert of SDU, and Shandong Provincial Excellent Doctor. Prof. Xu Feng presided over 12 projects, including 1 National Major Project, and 4 funded by National Natural Science Foundation. He established the first prospective cohort (more than 200,000 cases) and large database covering the whole country in the field of cardiac arrest in China, wrote the first cardiac arrest and resuscitation report in China, and established relevant and standard and norms. He found the common gene variation of acetaldehyde dehydrogenase 2 rs671 (red face gene), and revealed the "double-edged sword" effect of this gene variation on vascular disease. He also clarified the relevant core mechanism and the target of disease prevention and treatment, and optimized the emergency treatment plan of this kind of diseases. Prof. Xu Feng’s results were published in first-class journals as the first or corresponding author such as
European Heart Journal, Nature Communications, JAMA Cardiology, etc., cited by prestigious journals including
Nature, and reviewed by prestigious experts in the field from Harvard or Stanford, etc. One of his articles were selected by ESI highly cited papers, and one was awarded the “National Top Ten Medical Research (News)”. He has won the first prize of the Chinese Medical Science and Technology Award and the first and second prize of the Ministry of Education for 7 times, and has been invited to deliver special reports at first-class academic conferences at home and abroad for many times. He has been invited to write reviews for prestigious journals, and edited 3 national textbooks. Many of his postgraduate students won national scholarships and provincial postgraduate excellent achievements awards.
